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A new member of the endothelin/sarafotoxin family of vasoconstrlctor peptides. bibrotoxin (BTX), was isolated from the venom of the burrowing 
asp Atrucruspis bibronr by reversed-phase FPLC. The amino acid sequence of BTX differs from SRTX-b in the substitution Ala’ instead of LysJ. 
which suggests that it represents the peptide lsoform of Atructusprs bibroni corresponding to SRTX-b. BTX competed for [‘*51]ET-l bmding to 
human ET,-type receptor with a K, of 3.2 x IO-’ M compared to 4.2 x IO-’ M for SRTX-b. In rat thorax aorta BTX induced vasoconstrictions 
with a threshold concentration of 3 x 10mR M compared to 1 x 10m9 for ET-I. 
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1. INTRODUCTION 
The peptides of the mammalian endothelin family 
[1,2] and of the sarafotoxin family from the venom of 
the burrowing asp Atractaspis engaddensis [3,4] are very 
similar in structure. The comparative analysis of the 
receptor binding and the vasoconstrictor activity of the 
natural isotoxins [5.6], of synthetic analogues [7] and of 
peptide fragments [8] has contributed to the under- 
standing of the structure-function relationship of these 
peptides. The endothelins ET-l and -2, like their snake 
counterparts the sarafotoxins SRTX-a and -b, are 
strong vasoconstrictors, that bind to and act through 
the same receptors in vascular and brain tissue [5,9,10]. 
While the sequence of the endothelins with the excep- 
tion of mouse ET-2, i.e. vasoinstestinal contractor 
(VIC) [l I], is highly conserved among mammals from 
mice to humans, nothing is known about the presence 
of sarafotoxin-related peptides in other reptiles, either 
in their venom or in their circulatory system. Neither is 
it known, if these peptides are synthesized as pro-forms 
(big-sarafotoxin) that are subsequently processed by 
converting enzymes. 
In this paper we report the purification and char- 
acterisation of a novel peptide of the ET/SRTX family 
of peptides from the venom of the burrowing asp A trac- 
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taspis bibroni, a South African relative of the Middle 
Eastern A. engaddensis. 
2. EXPERIMENTAL 
ET- 1. ET-2. ET-3 and SRTX-b were purchased from Bachem (Hei- 
delberg, Germany). dissolved at 0.1 mM and stored at -20°C. A 
rabbit polyclonal antibody to ET-l was obtamed after immunisation 
with ET-I coupled to keyhole limpet hemocyanin using glutaralde- 
hyde; the IgG fraction was Isolated by Protein A-affinity chromatog- 
raphy and antibodles crossreacting with bigET-1 were removed by 
chromatography on bigET-Sepharose, 
Specimens of Atructaspis bibroni were captured m Natal and were 
held with authority from the Natal Parks Board. The venom from six 
of the snakes was collected by having them strike laterally through a 
layer of parafilm stretched over a plastic ring. Droplets of venom that 
collected on the distal surface of the parafilm were rinsed with distilled 
water into sample tubes, freeze-dried and stored at -80°C until further 
use. Lyophllized venom was reconstituted with water and, after re- 
moval of particulate material. applied to a reversed phase FPLC 
column (PepRPC HR 5/S; Pharmacia). The column was eluted with 
a gradient from 0% to 50% buffer B (buffer A: 0.1% TFA/H?O: buffer 
B: 0.085% TFA/acetonitnle) at 1 ml/min. 
Venom fractions obtained by reversed-phase FPLC were analysed 
by coating aliquots to microplate wells. These were blocked with 
PBS/O.OS% Tween 20 and developed with ET-l antibodies that cross- 
reacted with SRTXb and peroxldase-labeled goat anti-rabbit IgG 
(Sigma, Deisenhofen, Germany). 
Samples were analysed by RP-HPLC (Superspher RP-18, 4 pm. 
(250 x 4) mm, MZ-Analysentechnik GmbH, Mainz, Germany) using 
a gradient from 0% to 50% buffer B (buffer A: 0.1% TFAIH,O; buffer 
B: 0.085% TFA/acetonitnle) at 1 ml/min. Elutlon was monitored al 
214 and 280 nm. 
For the functlonal analysis of the fractions obtained from the 
venom by reversed-phase FPLC, aliquots were tested in a competltlve 
radio receptor assay using membranes of BHK cells stably trdnsfected 
with cloned human ET,-type receptor (unpublished results and [12]) 
and (3-[“51]iodotyrosyl) endothehn-1 ([““IlET-1; 2000 Ci/mmol -74 
TBqlmmol. Amersham) at a final concentration of 15 pM. Assays 
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Fig. 1. Analysis of A. bibroni toxin by reversed-phase FPLC and identification of bibrotoxin by ELISA and HPLC. Reconstitued toxin was 
equilibrated with H,O/O.l TFA, applied to a FPLC PepRPC HR 5/5 column and eluted exactly as described under Experimental Procedures (a); 
retention times of SRTX-b and ET-1 are indicated by arrows. Fractions of 1 ml were collected and aliquots of 10 ~1 of each fraction were coated 
to microtiter wells, which were developed as described under Experimental Procedures (b). 60~1 of fraction 35 were analyzed by HPLC as described 
under Experimental Procedures (c). 
were stopped by filtration on glass fiber filters (GF 25, Schleicher & 
Schiill) followed by three rapid washes with 0.5 ml of buffer. Non- 
specific binding was determined in the presence of unlabeled endothe- 
hn-l (ET-l) at a concentration of IO-’ M. Competition binding assays 
were performed using varying concentrations of competitors as indi- 
cated in the text. Mathmatical analysis of binding data was carried out 
using modified versions of the EBDA/LIGAND programs [13,14]. 
Sequence analysis of pyridylethylated reduced as well as untreated 
peptide was done using a model 477A protein sequencer wtth an 
on-line model 120A PTH analyzer (Applied Biosystems). 
The vasoactive ffect of bibrotoxin (BTX) was examined using iso- 
lated rings of rat thoracic aortae. Male Wistar rats (25&300 g, Scher- 
ing SPF) were killed by carbon dioxide inhalation. The thoracic aorta 
was prepared and the isometric tension was recorded essenttally as 
described elsewhere [15]. Briefly, the endothelium was removed by 
gently rubbing the internal surface with a watchmaker’s forceps. The 
rings were mounted under 2.0 g resting tension in 10 ml organ cham- 
bers (Schuler, Hugo-Sachs, Germany) containing physiological saline 
solution. The tissues were allowed to equilibrate for 60 min before 
being contracted by addition of 25 mM KC1 and, following the wash 
out, with phenylephrine (1 PM). The lack of acethylchohne (ACh)- 
induced (1 PM) relaxatron was taken as an indrcation of endothelium 
removal (E‘). The de-endothelialized rings were contracted with ET-l, 
SRTX-b, and BTX at the final concentrations indtcated. 
3. RESULTS AND DISCUSSION 
Venom obtained from individual specimens of 
A. bibroni revealed different compositions when analy- 
sed by reversed-phase chromatography, a phenomenon 
commonly observed in the analysis of snake venoms 
[16]. In the representative sample shown (Fig. la and b) 
ET-like immunoreactivity was found in a single frac- 
tion, which eluted at 27% CH,CNfTFA, corresponding 
to the retention time of SRTX-b in this system; ET-l 
eluted at 33%. The same fraction that contained the 
material reacting with the antibody, specifically com- 
peted for binding of [‘*‘I]ET-1 to membranes of BHK 
cells expressing human ET,-type receptor (not shown). 
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Fig. 2. Sequence of bibrotoxm in comparison to the endothelins and sarafotoxins. Amino acids common to all peptides of this family are boxed 
with rectangular corners. those shared by either the mammalian endothelins or the sarafotoxin family are boxed with round corners. The substitution 
that is unique to bibrotoxin (Ala“) is set in bold and those amino acids that are shared by the most active members of each family (ET-l and SRTX-b) 
are encircled. 
This fraction contained a homogeneous peptide, as de- 
termined by HPLC analysis (Fig. lc). 
Two aliquots of this peptide were used to determine 
its sequence; one was reduced and pyridylethylated be- 
fore both were sequenced. The sequence thus deter- 
mined is highly homologous to that of SRTX-b (Fig. 2) 
with the only difference being the substitution of Ala4 
instead of Lys4. This exchange appears to be less impor- 
tant for its functional activity, because it is the least 
conserved position with five different amino acids 
known in the nine peptides of this family. Moreover, it 
shares Ser2 with the sarafotoxins SRTX-a and -b as well 
as the endothelins-1 and -2, all of which are potent 
vasoconstrictors. It has been pointed out that this posi- 
tion may be important for the potency of these peptides 
in comparison to ET-3 and SRTX-c and -d that have 
Thr’ and exhibit poor activity [5]. Besides the ten amino 
acids that are identical in all peptides of this family, the 
novel peptide shares the six substitutions that are iden- 
tical within the sarafotoxins but are different from the 
endothelins. 
In a competitive binding assay using membranes of 
BHK cells stably transfected with human ET,-type re- 
ceptor, very similar competition curves were found for 
ET-l, SRTX-b and BTX-b (Fig. 3). Non-linear regres- 
sion analysis [14] of the data yielded a K, of 3.2 x 10m9 
M for BTX-b compared with 4.2 x 10e9 M for 
SRTX-b. 
ET- 1, BTX and SRTX-b contracted rat thoracic aor- 
tic preparations without endothelium in a concentra- 
tion-dependent manner (Fig. 4). The potency order was: 
ET-l Z- SRTX. BTX had a threshold concentration of 
3 x lo-’ M in denuded rings. Higher concentrations of 
BTX than indicated could not be tested due to the lim- 
ited availability of this peptide. The vehicle elicited no 
vasoactive effect. 
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In summary, this novel peptide clearly is a member 
of the snake ET-related peptides and most likely repre- 
sents the A. bibroni homologue of SRTX-b. Thus in 
analogy the name bibrotoxin(-b) (BTX) is proposed for 
this peptide. It is presently not known whether other 
bibrotoxins besides BTX exist, but a molecular biology 
approach using oligonucleotides derived from this se- 
quence should soon answer this question. It is to be 
expected that a precursor of bibrotoxin (big-bibrotoxin) 
as it is present in mammals (big-endothelin) can be iden- 
tified in these snakes. Given the specialized function of 
their venom glands it may be possible to identify and 
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Fig. 3. Competition of [“‘IlET-1 binding to ET-R, by ET-l. SRTX-b 
and BTX. Competitive binding assays were carried out as descrtbed 
under Experimental Procedures using ET-l (o), SRTX-b (0). and 
BTX (+) at the final concentrations indicated. 
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Fig. 4. Vasoactive effects of BTX in comparison to ET-l and SRTX-b. 
Contractions of rings of rat aorta induced by ET-I (e), SRTX-b (o), 
and BTX (+) in the absence of endotheIium. Each point represents an 
individual experiment. 
isolate the converting enzyme which in mammals has 
proven to be so elusive. 
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